Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,703 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 155 · Balance 6,703 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $772.76 · Expires 2036-01-02 | Direct | 1,962 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 1,962 · Balance 1,962 F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 21:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,962 | $0.00 Strike: $772.76 | $0.00 |
DisclosureSEC source: 0001225474-26-000002 · edgardoc.xml · derivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,962 Underlying: Common Stock · 1,962 shares Expires 2036-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001225474-26-000002 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,703 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,958 | $0.00 Strike: $719.37 | $0.00 |
DisclosureSEC source: 0001968202-25-000004 · edgardoc.xml · derivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,958 Underlying: Common Stock · 1,958 shares Expires 2035-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 166 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-25-000004 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,548 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,707 | $0.00 Strike: $625.60 | $0.00 |
DisclosureSEC source: 0001968202-24-000042 · edgardoc.xml · derivative · entry 3 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,707 shares Expires 2032-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 24, 2023. F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,707 | $950.00 | $2,571,650.00 |
DisclosureSEC source: 0001968202-24-000042 · edgardoc.xml · nonDerivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,382 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 24, 2023. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,707 | $625.60 | $1,693,499.20 |
DisclosureSEC source: 0001968202-24-000042 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 24, 2023. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,607 | $0.00 Strike: $888.34 | $0.00 |
DisclosureSEC source: 0001968202-24-000023 · edgardoc.xml · derivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,607 Underlying: Common Stock · 1,607 shares Expires 2034-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 135 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-24-000023 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,382 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,613 | $0.00 Strike: $482.68 | $0.00 |
DisclosureSEC source: 0001883850-23-000046 · edgardoc.xml · derivative · entry 3 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,613 shares Expires 2031-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,613 | $800.00 | $2,890,400.00 |
DisclosureSEC source: 0001883850-23-000046 · edgardoc.xml · nonDerivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,247 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,613 | $482.68 | $1,743,922.84 |
DisclosureSEC source: 0001883850-23-000046 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,929 | $0.00 Strike: $725.89 | $0.00 |
DisclosureSEC source: 0001883850-23-000018 · edgardoc.xml · derivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,929 Underlying: Common Stock · 1,929 shares Expires 2033-01-03 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 165 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-23-000018 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,247 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,431 | $0.00 Strike: $374.12 | $0.00 |
DisclosureSEC source: 0001883850-22-000032 · edgardoc.xml · derivative · entry 3 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,431 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,431 | $700.00 | $1,701,700.00 |
DisclosureSEC source: 0001883850-22-000032 · edgardoc.xml · nonDerivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,082 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,431 | $374.12 | $909,485.72 |
DisclosureSEC source: 0001883850-22-000032 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,707 | $0.00 Strike: $625.60 | $0.00 |
DisclosureSEC source: 0001708138-22-000006 · edgardoc.xml · derivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,707 Underlying: Common Stock · 2,707 shares Expires 2032-01-03 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 191 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-22-000006 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,082 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,479 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001708138-21-000076 · edgardoc.xml · derivative · entry 3 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,479 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,479 | $650.00 | $1,611,350.00 |
DisclosureSEC source: 0001708138-21-000076 · edgardoc.xml · nonDerivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,891 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,479 | $380.95 | $944,375.05 |
DisclosureSEC source: 0001708138-21-000076 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,930 | $0.00 Strike: $374.12 | $0.00 |
DisclosureSEC source: 0001237899-21-000008 · edgardoc.xml · derivative · entry 3 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,431 Underlying: Common Stock · 1,930 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,930 | $525.00 | $1,013,250.00 |
DisclosureSEC source: 0001237899-21-000008 · edgardoc.xml · nonDerivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,891 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,930 | $374.12 | $722,051.60 |
DisclosureSEC source: 0001237899-21-000008 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,613 | $0.00 Strike: $482.68 | $0.00 |
DisclosureSEC source: 0001237899-21-000001 · edgardoc.xml · derivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,613 Underlying: Common Stock · 3,613 shares Expires 2031-01-04 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 248 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-21-000001 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,891 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 9,212 | $0.00 Strike: $520.01 | $0.00 |
DisclosureSEC source: 0001237899-20-000043 · edgardoc.xml · derivative · entry 3 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,212 shares Expires 2026-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9,212 | $600.00 | $5,527,200.00 |
DisclosureSEC source: 0001237899-20-000043 · edgardoc.xml · nonDerivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,643 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 9,212 | $520.01 | $4,790,332.12 |
DisclosureSEC source: 0001237899-20-000043 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 22, 2020 Filed Sep 23, 2020 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 20 | $552.36 | $11,047.20 |
DisclosureSEC source: 0001708138-20-000105 · edgardoc.xml · nonDerivative · entry 16 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,643 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,960 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001708138-20-000105 · edgardoc.xml · derivative · entry 19 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,479 Underlying: Common Stock · 4,960 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,830 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001708138-20-000105 · edgardoc.xml · derivative · entry 18 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,830 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,784 | $0.00 Strike: $371.40 | $0.00 |
DisclosureSEC source: 0001708138-20-000105 · edgardoc.xml · derivative · entry 17 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,784 shares Expires 2029-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,530 | $555.74 | $850,282.20 |
DisclosureSEC source: 0001708138-20-000105 · edgardoc.xml · nonDerivative · entry 15 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,663 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 1,530 shares of Company stock on September 21, 2020 at prices ranging from $555.51 to $556.04. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 21, 2020 at each separate price. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 899 | $554.82 | $498,783.18 |
DisclosureSEC source: 0001708138-20-000105 · edgardoc.xml · nonDerivative · entry 14 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,193 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 899 shares of Company stock on September 21, 2020 at prices ranging from $554.32 to $555.22. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 21, 2020 at each separate price. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,101 | $553.17 | $609,040.17 |
DisclosureSEC source: 0001708138-20-000105 · edgardoc.xml · nonDerivative · entry 13 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,092 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 1,101 shares of Company stock on September 21, 2020 at prices ranging from $552.69 to $553.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 21, 2020 at each separate price. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 513 | $552.01 | $283,181.13 |
DisclosureSEC source: 0001708138-20-000105 · edgardoc.xml · nonDerivative · entry 12 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,193 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 513 shares of Company stock on September 21, 2020 at prices ranging from $551.69 to $552.51. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 21, 2020 at each separate price. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,501 | $551.09 | $827,186.09 |
DisclosureSEC source: 0001708138-20-000105 · edgardoc.xml · nonDerivative · entry 11 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,706 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 1,501 shares of Company stock on September 21, 2020 at prices ranging from $550.64 to $551.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 21, 2020 at each separate price. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,600 | $550.11 | $880,176.00 |
DisclosureSEC source: 0001708138-20-000105 · edgardoc.xml · nonDerivative · entry 10 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,207 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 1,600 shares of Company stock on September 21, 2020 at prices ranging from $549.62 to $550.52. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 21, 2020 at each separate price. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,600 | $549.07 | $1,427,582.00 |
DisclosureSEC source: 0001708138-20-000105 · edgardoc.xml · nonDerivative · entry 9 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,807 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 2,600 shares of Company stock on September 21, 2020 at prices ranging from $548.62 to $549.60. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 21, 2020 at each separate price. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,654 | $548.13 | $2,002,867.02 |
DisclosureSEC source: 0001708138-20-000105 · edgardoc.xml · nonDerivative · entry 8 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,407 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 3,654 shares of Company stock on September 21, 2020 at prices ranging from $547.61 to $548.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 21, 2020 at each separate price. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,356 | $547.28 | $742,111.68 |
DisclosureSEC source: 0001708138-20-000105 · edgardoc.xml · nonDerivative · entry 7 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,061 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 1,356 shares of Company stock on September 21, 2020 at prices ranging from $546.57 to $547.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 21, 2020 at each separate price. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 800 | $546.01 | $436,808.00 |
DisclosureSEC source: 0001708138-20-000105 · edgardoc.xml · nonDerivative · entry 6 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,417 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 800 shares of Company stock on September 21, 2020 at prices ranging from $545.56 to $546.53. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 21, 2020 at each separate price. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 700 | $544.96 | $381,472.00 |
DisclosureSEC source: 0001708138-20-000105 · edgardoc.xml · nonDerivative · entry 5 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,217 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 700 shares of Company stock on September 21, 2020 at prices ranging from $544.49 to $545.37. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 21, 2020 at each separate price. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $543.19 | $162,957.00 |
DisclosureSEC source: 0001708138-20-000105 · edgardoc.xml · nonDerivative · entry 4 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,917 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 300 shares of Company stock on September 21, 2020 at prices ranging from $542.66 to $543.48. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 21, 2020 at each separate price. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 7,830 | $376.69 | $2,949,482.70 |
DisclosureSEC source: 0001708138-20-000105 · edgardoc.xml · nonDerivative · entry 3 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 4,960 | $380.95 | $1,889,512.00 |
DisclosureSEC source: 0001708138-20-000105 · edgardoc.xml · nonDerivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,784 | $371.40 | $1,405,377.60 |
DisclosureSEC source: 0001708138-20-000105 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 21, 2020 Filed Aug 24, 2020 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $617.18 | $617,180.00 |
DisclosureSEC source: 0001237899-20-000036 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,643 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.